Role of tissue transglutaminase and effect of cantharidinate in human colorectal cancer

Yang,Lan‑Lan; Liang,Chong‑Yang; Lu,Tian‑Cheng; Zhi,Chen‑Yang; Liu,Bin; Zhou,Jian‑Hua; Liu,Xu‑Ming; Gao,Hai‑Cheng; Huang,Wei

doi:10.3892/mmr.2013.1706

Role of tissue transglutaminase and effect of cantharidinate in human colorectal cancer

Authors:
- Lan‑Lan Yang
- Chong‑Yang Liang
- Tian‑Cheng Lu
- Chen‑Yang Zhi
- Bin Liu
- Jian‑Hua Zhou
- Xu‑Ming Liu
- Hai‑Cheng Gao
- Wei Huang
View Affiliations

Affiliations: Department of Gastroenterology and Hepatology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Department of Clinical Pharmacy and Pharmaceutical Management, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 13002, P.R. China, School of Life Sciences, Jilin Agricultural Univesity, Changchun, Jilin 130118, P.R. China, Changchun University of Traditional Chinese Medicine, Changchun, Jilin 130118, P.R. China, Department of General Surgery, Jilin University Second Hospital, Changchun, Jilin 130041, P.R. China, Department of Radiotherapy, Tumor Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: September 27, 2013 https://doi.org/10.3892/mmr.2013.1706
Pages: 1812-1816

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of tissue transglutaminase (tTG) in cancer development remains an important field of study. The aim of the current study was to understand the involvement of tTG in cancer and the inhibitory effect of cantharidinate on the expression of tTG in human colorectal cancer (CRC) using immunohistochemical and PCR analysis. The results showed that the expression of tTG increased in human CRC and cantharidinate inhibited the expression of tTG. These results suggested that tTG is significant in human CRC and that tTG may be an important target for tumor chemoprevention and treatment. Cantharidinate may be considered as a novel co‑therapy for controlling tTG expression in human CRC.

View Figures

View References

1	Deng X, Cao Y, Liu Y, Li F, Sambandam K, Rajaraman S, Perkins AS, Fields AP, Hellmich MR, Townsend CM Jr, et al: Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer. Mol Carcinog. 52:255–264. 2013.PubMed/NCBI
2	Potter JD: Colorectal cancer: molecules and populations. J Natl Cancer Inst. 91:916–932. 1999. View Article : Google Scholar : PubMed/NCBI
3	Deschoolmeester V, Baay M, Specenier P, Lardon F and Vermorken JB: A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 15:699–731. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kotzev I, Mirchev M, Manevska B, Ivanova I and Kaneva M: Risk and protective factors for development of colorectal polyps and cancer (Bulgarian experience). Hepatogastroenterology. 55:381–387. 2008.PubMed/NCBI
5	Domínguez-Ayala M, Díez-Vallejo J and Comas-Fuentes A: Missed opportunities in early diagnosis of symptomatic colorectal cancer. Rev Esp Enferm Dig. 104:343–349. 2012.PubMed/NCBI
6	Jass JR: Colorectal cancer: a multipathway disease. Crit Rev Oncog. 12:273–287. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
8	Posner MR: Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist. 10(Suppl 3): 11–19. 2005. View Article : Google Scholar : PubMed/NCBI
9	Simoglou C, Gymnopoulou E, Simoglou L, Gymnopoulou M, Nikolaou K and Gymnopoulos D: Surgery for colorectal cancer in the small town of Komotini. J Multidiscip Healthc. 5:273–276. 2012. View Article : Google Scholar : PubMed/NCBI
10	Hu Y, Zhang H, Xiong X, Cao Y, Han Y and Xi Z: Inhibitory effect of tissue transglutaminase (tTG) antisense oligodeoxynucleotides on tTG expression in cultured bovine trabecular meshwork cells. J Huazhong Univ Sci Technolog Med Sci. 25:729–731. 2005. View Article : Google Scholar
11	van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ and George J: Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 27:4089–4095. 2009.
12	Gerber DE: Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 77:311–319. 2008.PubMed/NCBI
13	Dehmer GJ, Douglas JS Jr, Abizaid A, et al: SCAI/ACCF/HRS/ESC/SOLACI/APSIC statement on the use of live case demonstrations at cardiology meetings: assessments of the past and standards for the future. Heart Rhythm. 7:1522–1535. 2010. View Article : Google Scholar
14	Liu HG and Huang HX: Overview pharmacokinetic about traditional Chinese medicine in recent 10 years. Zhongguo Zhong Yao Za Zhi. 32:2346–2348. 2007.(In Chinese).
15	Honkanen RE: Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett. 330:283–286. 1993. View Article : Google Scholar : PubMed/NCBI
16	Deng LP, Dong J, Cai H and Wang W: Cantharidin as an antitumor agent: a retrospective review. Curr Med Chem. 20:159–166. 2013. View Article : Google Scholar : PubMed/NCBI
17	Huang YP, Ni CH, Lu CC, et al: Suppressions of migration and invasion by cantharidin in TSGH-8301 human bladder carcinoma cells through the inhibitions of matrix metalloproteinase-2/-9 signaling. Evid Based Complement Alternat Med. 2013:1902812013. View Article : Google Scholar : PubMed/NCBI
18	Zhan YP, Huang XE, Cao J, et al: Clinical study on safety and efficacy of Qinin^® (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev. 13:4773–4776. 2012.PubMed/NCBI
19	Kim YM, Ku MJ, Son YJ, Yun JM, Kim SH and Lee SY: Anti-metastatic effect of cantharidin in A549 human lung cancer cells. Arch Pharm Res. 36:479–484. 2013. View Article : Google Scholar : PubMed/NCBI
20	Yeh CH, Yang YY, Huang YF, Chow KC and Chen MF: Induction of apoptosis in human Hep3B hepatoma cells by norcantharidin through a p53 independent pathway via TRAIL/DR5 signal transduction. Chin J Integr Med. 18:676–682. 2012. View Article : Google Scholar : PubMed/NCBI
21	Agnihotri N, Kumar S and Mehta K: Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res. 15:2022013. View Article : Google Scholar : PubMed/NCBI
22	Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ and Matei D: Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer. Neoplasia. 15:609–619. 2013.PubMed/NCBI
23	Caffarel MM, Chattopadhyay A, Araujo AM, Bauer J, Scarpini CG and Coleman N: Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma. J Pathol. 231:168–179. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wang Z, Perez M, Caja S, Melino G, Johnson TS, Lindfors K and Griffin M: A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis. Cell Death Dis. 4:e8082013. View Article : Google Scholar : PubMed/NCBI